Sesen Bio (Sesen Bio) 5-Year Yield-on-Cost % : 0.00 (As of May. 05, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sesen Bio 5-Year Yield-on-Cost %?

Sesen Bio's yield on cost for the quarter that ended in Dec. 2022 was 0.00.

The historical rank and industry rank for Sesen Bio's 5-Year Yield-on-Cost % or its related term are showing as below:

SESN's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.895
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Sesen Bio's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Sesen Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sesen Bio's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sesen Bio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Sesen Bio's 5-Year Yield-on-Cost % falls into.

Sesen Bio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Sesen Bio is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Sesen Bio (NAS:SESN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Sesen Bio 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Sesen Bio's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sesen Bio (Sesen Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sesen Bio Inc (NAS:SESN) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, Suite 1800, Cambridge, MA, USA, 02142

Website

https://www.sesenbio.com

Sesen Bio Inc is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company's product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive CIS of the bladder in patients previously treated with adequate or less than adequate BCG.

Executives

Modernatx, Inc.	10 percent owner	200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly	director, officer: President and CEO	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris	officer: Chief Financial Officer	397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Bjorn Odlander	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Michael Klichinsky	officer: Chief Scientific Officer	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits	director	C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Elly Ryu	officer: Principal Accounting Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Glen C Macdonald	officer: Chief Technology Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Monica Forbes	officer: Chief Financial Officer	3344 NORTH TORREY PINES CT., SUITE 200, SAN DIEGO CA 92037
Thomas R Cannell	director, officer: President and CEO	C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Mark Sullivan	officer: General Counsel & Secretary	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054